Each of its prospective purchasers shall have until January 10, 2023, to determine whether to make an offer.
HZNP, or Horizon Pharma PLC, is a pharmaceutical company based in Dublin, Ireland. The company specializes in developing and commercializing medicines and therapies to treat rare diseases. HZNP is a publicly traded company on the NASDAQ stock exchange. The company was founded in 2005 by Dr. Timothy Walbert, with a mission to bring treatments to those suffering from rare diseases. Since its inception, the company has grown to become one of the world’s leading rare disease companies, with a portfolio of over 20 medicines and therapies.
HZNP’s products are used to treat a variety of conditions, including respiratory and metabolic disorders, arthritis, and ophthalmic diseases. HZNP’s products are sold in over 40 countries around the world, and the company has a strong presence in the United States and Europe. In 2019, HZNP acquired Raptor Pharmaceuticals for $800 million. This acquisition further expanded the company’s product portfolio, with the addition of four approved therapies and a pipeline of development programs.
The company is well known for its medication to treat a thyroid eye condition, Tepezza. The pandemic-related supply chain issues have impacted Tepezza sales. Additionally, it offers Uplizna, which treats an inflammatory condition of the spinal cord and optic nerves, and Krystexxa, a medication for treating persistent gout.
HZNP’s stock price has been steadily increasing since it was first listed on the NASDAQ in 2014. The company’s stock has gained over 300% over the last five years, making it one of the best-performing stocks in the healthcare sector. Investors have been drawn to HZNP’s strong growth potential and focus on rare diseases, as well as its strong financials. With a strong balance sheet, no debt, and strong cash flow, HZNP is well-positioned for continued growth in the future, with a robust pipeline of new products. The company is also investing in its research and development efforts, with the goal of bringing new treatments to those suffering from rare diseases. Investors looking for exposure to the healthcare sector may want to consider adding HZNP to their portfolios.
Bidding on HZNP
On Nov. 30, the day after it disclosed the prospective acquisition offers, HZNP stock experienced a surge. In the days since shares have been trending higher. The three-day sprint was reversed on Monday, although shares are still above their important moving averages. The reverse was due to Johnson & Johnson (JNJ) dropping out of the bidding process.
JNJ has disclosed a $16.6 billion plan to purchase the medical equipment manufacturer Abiomed (ABMD). Due to the decision, only Amgen (AMGN) and Sanofi (SNY) are still in the running to acquire Horizon Pharma. The deadline for each of its potential buyers to decide whether to submit an offer is January 10th, 2023.
AI Trading
The main advantage of using AI trading for stock market research is that it can examine more assets objectively and continuously at all times of the day. We can improve decision-making, outcome modeling and forecasting, and market information by combining big data analytics with our AI prediction system.
Below is our stock pick from our 1 week stock forecast publicly announcing HZNP as a buy on Friday, November 25th, 2022 to our subscribers getting exclusive market insights based on artificial intelligence. This stock pick has been available in multiple forecasts continuously over various time frames in November. As a subscriber, when you view your forecasts published daily, you can recognize better opportunities by looking for repetition of certain stock picks repeatedly remaining in the AI forecasts. Another indicator is when you see the stock pick appear in multiple forecasted time frames, especially over multiple forecasts published each morning EST.
Click here to see the original forecast published on November 25th, 2022.
The Signal Confidence (SC) in this stock forecast is 41%, which is quite high for only a weekly time frame. When combined with machine learning, these incredibly intricate mathematical functions for statistical programming and modeling are capable of comparing their current coefficients and algorithms to newly added data and then adapting to improve the models' accuracy through a process of validation and reflection. The AI system computes the Signal Confidence (SC), which is expressed as a percentage out of 100%, based on the historical accuracy of each previous financial stock prediction, as well as current market factors relevant to stock pricing.
Stock Ticker | Open: Nov 25, 2022 | Close: Dec 2, 2022 | ROI% |
Horizon Therapeutics (HZNP) | $77.85 | $104.85 | 34.68% |
Subscribers who bought HZNP stock based on our AI Forecast for the 1-week time frame on November 25th, 2022 would have generated a significant short-term profit of 34.68% or $27 per share on this single trade. Discretion should always be used when analyzing the market. Your own due diligence is always required and you should always get advice from a licensed & certified financial counselor prior to implementing any financial plans.
Enhanced Market Intelligence
Finding market opportunities is made easier by using our AI system. It doesn't tell you what to do. It tells you where to look. Our skilled team of analysts carefully verifies the AI outputs and enhances this market research with a human touch, providing our subscribers with enhanced market intelligence. If you would like the AI advantage working for you, then you should subscribe today!
Life is better when you can be bullish.
Sources: 1. Horizon Therapeutics Investor Relations, "Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer" (2022)
Comments